ELTX
Income statement / Annual
Last year (2024), Elicio Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Elicio Therapeutics, Inc.'s net income was -$51.90 M.
See Elicio Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$28.31 M |
$2.88 M |
$1.49 M |
$4.03 M |
$6.58 M |
$7.30 M |
| Cost of Revenue |
$1.18 M
|
$1.17 M
|
$1.06 M
|
$1.23 M
|
$1.82 M
|
$1.14 M
|
$380.00 K
|
$3.17 M
|
$3.67 M
|
| Gross Profit |
-$1.18 M
|
-$1.17 M
|
-$1.06 M
|
$27.08 M
|
$1.06 M
|
$351.00 K
|
$3.65 M
|
$3.41 M
|
$3.62 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0.96
|
0.37
|
0.24
|
0.91
|
0.52
|
0.5
|
| Research and Development Expenses |
$33.66 M
|
$22.68 M
|
$17.05 M
|
$48.61 M
|
$38.88 M
|
$29.79 M
|
$9.15 M
|
$196.01 K
|
$0.00
|
| General & Administrative Expenses |
$11.33 M
|
$11.90 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.33 M
|
$11.90 M
|
$5.63 M
|
$17.78 M
|
$17.46 M
|
$9.16 M
|
$8.84 M
|
$3.61 M
|
$4.04 M
|
| Other Expenses |
-$1.18 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$43.81 M
|
$34.58 M
|
$22.68 M
|
$66.39 M
|
$56.34 M
|
$38.94 M
|
$17.99 M
|
$3.81 M
|
$4.04 M
|
| Cost And Expenses |
$44.99 M
|
$35.75 M
|
$23.73 M
|
$67.62 M
|
$58.15 M
|
$40.08 M
|
$18.37 M
|
$6.98 M
|
$7.72 M
|
| Interest Income |
$777.00 K
|
$373.00 K
|
$64.83 K
|
$3.39 K
|
$0.00
|
$81.48 K
|
$252.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$455.00 K
|
$1.06 M
|
$3.60 M
|
$876.44 K
|
$8.85 M
|
$0.00
|
$0.00
|
$300.43 K
|
$307.45 K
|
| Depreciation & Amortization |
$1.18 M
|
$1.17 M
|
$1.06 M
|
$801.00 K
|
$628.00 K
|
$496.00 K
|
$2.00 K
|
$460.34 K
|
$463.22 K
|
| EBITDA |
-$50.27 M |
-$32.97 M |
-$23.55 M |
-$51.93 M |
-$70.63 M |
-$40.16 M |
-$14.34 M |
$62.54 K |
$1.96 M |
| EBITDA Ratio |
0
|
0
|
0
|
-1.83
|
-24.53
|
-27.01
|
-3.56
|
0.01
|
0.27
|
| Operating Income Ratio |
0
|
0
|
0
|
-1.39
|
-19.19
|
-25.95
|
-3.56
|
-0.06
|
-0.06
|
| Total Other Income/Expenses Net |
-$6.91 M
|
$550.00 K
|
-$4.48 M
|
-$15.27 M
|
-$24.83 M
|
-$2.07 M
|
-$5.68 M
|
$2.13 M
|
$1.61 M
|
| Income Before Tax |
-$51.90 M
|
-$35.20 M
|
-$28.21 M
|
-$54.57 M
|
-$80.11 M
|
-$40.66 M
|
-$20.03 M
|
$1.73 M
|
$1.19 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-1.93
|
-27.81
|
-27.34
|
-4.97
|
0.26
|
0.16
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$452.78 K
|
$201.86 K
|
| Net Income |
-$51.90 M
|
-$35.20 M
|
-$28.21 M
|
-$26.40 M
|
-$80.11 M
|
-$40.66 M
|
-$20.03 M
|
$632.24 K
|
$307.30 K
|
| Net Income Ratio |
0
|
0
|
0
|
-0.93
|
-27.81
|
-27.34
|
-4.97
|
0.1
|
0.04
|
| EPS |
-4.25 |
-6.96 |
-9.1 |
-19.32 |
-1.93 |
-1.5 |
-6.79 |
103.31 |
50.21 |
| EPS Diluted |
-4.25 |
-6.96 |
-9.1 |
-19.32 |
-1.93 |
-1.5 |
-6.79 |
103.31 |
50.21 |
| Weighted Average Shares Out |
$12.20 M
|
$5.06 M
|
$3.10 M
|
$3.20 M
|
$8.15 M
|
$8.15 M
|
$2.95 M
|
$6.12 K
|
$6.12 K
|
| Weighted Average Shares Out Diluted |
$12.20 M
|
$5.06 M
|
$3.10 M
|
$3.20 M
|
$8.15 M
|
$8.15 M
|
$2.95 M
|
$6.12 K
|
$6.12 K
|
| Link |
|
|
|
|
|
|
|
|
|
